Table 1. Key uses and findings of Active Bacterial Core surveillance data for vaccine development, evaluation, and policy formulation*.

Pathogen	Vaccines	Key uses and findings
Streptococcus pneumoniae	PCV7 and PCV13	Selection of serotypes included in PCV7and PCV13
		Informed ACIP recommendations for children <5 y of age
		Tracking postlicensure declines in cases
		Documented effectiveness of PCV7
		Monitoring incidence of nonvaccine serotypes
		Accelerated regulatory approval of PCV13
		Informed ACIP recommendations for PCV13 use in immunocompromised adults and children
Neisseria meningitidis	Conjugate vaccines, serogroup B vaccines	Informed ACIP recommendations for children 11–18 y of age
		Informed ACIP recommendations for booster dose
		Documented vaccine effectiveness
		Informed ACIP infant meningococcal recommendations
		Evaluated potential effect on serogroup B disease in United States
Haemophilus influenzae	Hib vaccine	Tracking postlicensure declines in Hib disease
		Tracking shift toward non-Hib disease;
		Evaluated effect of vaccine shortages
Group A Streptococcus	M-type vaccine (under development)	Estimated degrees of protection against severe group A streptococcal infections
Group B Streptococcus	Trivalent vaccine (under development)	Informing development of vaccine to prevent early-onset (within 1 week of life) group B streptococcal disease
Methicillin-resistant Staphylococcus aureus	S. aureus vaccine (under development)	Determining population groups to target

*ACIP, Advisory Committee on Immunization Practices; Hib, H. influenzae type b vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. An expanded version of this table with references is available in the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/21/9/14-1333-Techapp1.pdf).